AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24953333 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib monotherapy (250 mg/day)
Number of subjects: 236
Study 24953333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin followed by gefitinib maintenance
Number of subjects: 236
Study 24953333 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib monotherapy
Number of subjects: 236
Study 22762856 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (571-mg metformin acetate)
Number of subjects: 30
Study 22762856 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (500-mg metformin hydrochloride)
Number of subjects: 30
Study 18089552 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychoeducational support program
Number of subjects: 190
Study 17044764 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice nurse (APN) strategies for coordinating care during transition from hospital to home
Number of subjects: 0
Study 17044764 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12885448 — intervention group
Group type: EXPERIMENTAL
Intervention: 35Gy in ten fractions
Number of subjects: 0
Study 12885448 — intervention group
Group type: COMPARATOR
Intervention: 60Gy in 30 fractions
Number of subjects: 0
Study 10680787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg daily for 4 weeks, then 10 mg daily for 1 year, followed by gradual withdrawal over 16 weeks)
Number of subjects: 138
Study 10680787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 10680787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 138
Study 9314342 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite avoidance treatment (Acarosan applied to floors, impermeable covers for mattresses and bedding)
Number of subjects: 29
Study 9314342 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite avoidance treatment
Number of subjects: 29
Study 9314342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water applied to floors, cotton covers for mattresses)
Number of subjects: 29
Study 8153034 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic patient education about cough
Number of subjects: 5890
Study 8153034 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no systematic education)
Number of subjects: 5890
Study 3707872 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microamperes (50 Hz) electric currents, continuous exposure for 5.5 hours on the second day
Number of subjects: 76
Study 3707872 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control group)
Number of subjects: 76
Study 29745073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of colloid (10mg/kg) and crystalloid solutions
Number of subjects: 55
Study 29745073 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solutions only
Number of subjects: 55
Study 27917214 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise training for six months in addition to medical treatment
Number of subjects: 80
Study 27917214 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 80
Study 23767772 — intervention group
Group type: EXPERIMENTAL
Intervention: VUKA family-based program (10 sessions over approximately 3 months)
Number of subjects: 65
Study 21885212 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 77
Study 21885212 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 77
Study 19951979 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade) at an initial dose of 20 mg/kg/day for patients receiving 2‐4 packed red blood cell units/month, 10 mg/kg/day for patients receiving less frequent transfusions, and 30 mg/kg/day for patients receiving more frequent transfusions.
Number of subjects: 1744
Study 19951979 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade) with dose adjustments based on 3‐month serum ferritin trends and continuous assessment of safety markers.
Number of subjects: 1744
Study 18671874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment in infants (IPTi)
Number of subjects: 0
Study 16848649 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 49
Study 12914721 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric surgery
Number of subjects: 0
Study 12914721 — intervention group
Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 0
Study 11100392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at classic acupuncture points
Number of subjects: 48
Study 11100392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 'tender' points
Number of subjects: 48
Study 11100392 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (minimal needling at non-acupuncture points)
Number of subjects: 48
Study 11100392 — intervention group
Group type: COMPARATOR
Intervention: Control (20 min rest)
Number of subjects: 48
Study 8811150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours bed rest after sheath removal
Number of subjects: 86
Study 8811150 — intervention group
Group type: COMPARATOR
Intervention: 6 hours bed rest after sheath removal
Number of subjects: 86
Study 1422616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (225 mg/day from week 5)
Number of subjects: 30
Study 1422616 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine (75 mg/day from week 5)
Number of subjects: 30
Study 3852899 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspoxicillin (ASPC) 2 g administered intravenously twice a day for 7 days
Number of subjects: 154
Study 3852899 — intervention group
Group type: COMPARATOR
Intervention: Sulbenicillin (SBPC) 2 g administered intravenously twice a day for 7 days
Number of subjects: 154
Study 31928758 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate (MOD) feeding rate of milk replacer (0.64 to 0.66 kg of dry matter (DM)/d for the first 35 to 39 d)
Number of subjects: 491
Study 31928758 — intervention group
Group type: COMPARATOR
Intervention: High (HI) feeding rate of milk replacer (0.92 to 1.07 kg of DM/d for the first 35 to 44 d)
Number of subjects: 491
Study 31928758 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate (MOD) feeding rate of milk replacer
Number of subjects: 491
Study 31928758 — intervention group
Group type: COMPARATOR
Intervention: High (HI) feeding rate of milk replacer
Number of subjects: 491
Study 29097028 — intervention group
Group type: EXPERIMENTAL
Intervention: bezlotoxumab 10 mg/kg
Number of subjects: 95
Study 29097028 — intervention group
Group type: EXPERIMENTAL
Intervention: actoxumab 10 mg/kg + bezlotoxumab 10 mg/kg
Number of subjects: 95
Study 29097028 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study 26826355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (IV OT) at doses of 0.1 IU/kg, 1 IU/kg, and 5 IU/kg
Number of subjects: 4
Study 26826355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN OT) at doses of 0.1 IU/kg, 1 IU/kg, and 5 IU/kg
Number of subjects: 4
Study 25680840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized aqueous extract of M. officinalis leaves (500 mg twice a day for 14 days)
Number of subjects: 71
Study 25680840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 22851045 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-supported education (MME)
Number of subjects: 203
Study 22851045 — intervention group
Group type: COMPARATOR
Intervention: Standard education (SE)
Number of subjects: 203
Study 20386035 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 175
Study 20386035 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face office visits
Number of subjects: 175
Study 18162446 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5mg oral administration)
Number of subjects: 0
Study 18162446 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine (internal standard)
Number of subjects: 0
Study 16722397 — intervention group
Group type: EXPERIMENTAL
Intervention: E-selectin measured by enzyme linked immunosorbent assay in nasal polyps
Number of subjects: 34
Study 16722397 — intervention group
Group type: EXPERIMENTAL
Intervention: E-selectin expression in vascular endothelial and matrix of nasal polyps
Number of subjects: 34
Study 16722397 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of E-selectin expression in vascular endothelial and matrix
Number of subjects: 34
Study 14518696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (45 mg, 67.5 mg, or 90 mg twice daily) with background ARV regimen
Number of subjects: 71
Study 14518696 — intervention group
Group type: COMPARATOR
Intervention: Control group (background ARV regimen alone)
Number of subjects: 71
Study 14518696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (combined groups)
Number of subjects: 71
Study 14518696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 14518696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (all doses)
Number of subjects: 71
Study 10996576 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin nasal spray 200 IU
Number of subjects: 1255
Study 10996576 — intervention group
Group type: COMPARATOR
Intervention: Salmon calcitonin nasal spray 100 IU
Number of subjects: 1255
Study 10996576 — intervention group
Group type: COMPARATOR
Intervention: Salmon calcitonin nasal spray 400 IU
Number of subjects: 1255
Study 10996576 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin nasal spray (all active treatment groups)
Number of subjects: 1255
Study 9105062 — intervention group
Group type: EXPERIMENTAL
Intervention: LTD4 (mean cumulative concentration: 95.7 microM)
Number of subjects: 12
Study 9105062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (mean cumulative concentration: 542 mM)
Number of subjects: 12
Study 9105062 — intervention group
Group type: COMPARATOR
Intervention: Diluent (PBS/ethanol or PBS)
Number of subjects: 12
Study 9105062 — intervention group
Group type: EXPERIMENTAL
Intervention: LTD4
Number of subjects: 12
Study 9105062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 12
Study 1359803 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1
Number of subjects: 30
Study 1359803 — intervention group
Group type: COMPARATOR
Intervention: vecuronium 0.1 mg.kg‐1
Number of subjects: 30
Study 3541420 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg isosorbide‐5‐mononitrate
Number of subjects: 15
Study 3541420 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg isosorbide‐5‐mononitrate
Number of subjects: 15
Study 3541420 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg isosorbide‐5‐mononitrate
Number of subjects: 15
Study 3541420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31576791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 1383
Study 31576791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/day
Number of subjects: 1383
Study 31576791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1383
Study 30265963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker-soled shoes
Number of subjects: 31
Study 30265963 — intervention group
Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 31
Study 29070158 — intervention group
Group type: EXPERIMENTAL
Intervention: SH plus MTA
Number of subjects: 80
Study 29070158 — intervention group
Group type: EXPERIMENTAL
Intervention: SS plus MTA
Number of subjects: 80
Study 29070158 — intervention group
Group type: EXPERIMENTAL
Intervention: SH plus CH
Number of subjects: 80
Study 29070158 — intervention group
Group type: EXPERIMENTAL
Intervention: SS plus CH
Number of subjects: 80
Study 26385172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior iliac simulation
Number of subjects: 0
Study 26385172 — intervention group
Group type: COMPARATOR
Intervention: No prior iliac simulation
Number of subjects: 0
Study 23339225 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (multivitamin with iron)
Number of subjects: 150
Study 23339225 — intervention group
Group type: COMPARATOR
Intervention: Control (multivitamin)
Number of subjects: 150
Study 21832218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole ER
Number of subjects: 523
Study 21832218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole IR
Number of subjects: 523
Study 21832218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 19859954 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent implantation
Number of subjects: 73
Study 19859954 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (PTA)
Number of subjects: 73
Study 17080880 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + Clearfil tri‐S Bond (Kuraray)
Number of subjects: 35
Study 17080880 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + Clearfil Protect Bond (Kuraray)
Number of subjects: 35
Study 17080880 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + Single Bond 2 (3M‐ESPE)
Number of subjects: 35
Study 17080880 — intervention group
Group type: COMPARATOR
Intervention: Conventional method + Clearfil Protect Bond
Number of subjects: 35
Study 17080880 — intervention group
Group type: COMPARATOR
Intervention: Conventional method + Clearfil tri‐S Bond
Number of subjects: 35
Study 17080880 — intervention group
Group type: COMPARATOR
Intervention: Conventional method + 37% H3PO4 + Single Bond 2
Number of subjects: 35
Study 14981126 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable long-bar overdentures
Number of subjects: 30
Study 14981126 — intervention group
Group type: COMPARATOR
Intervention: Maxillary fixed prostheses
Number of subjects: 30
Study 14981126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures with palates
Number of subjects: 30
Study 14981126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures without palates
Number of subjects: 30
Study 11344712 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTPAC (FP)
Number of subjects: 41
Study 11344712 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Standard (SS)
Number of subjects: 41
Study 11344712 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Fast (SF)
Number of subjects: 41
Study 9046389 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g of ethanol/kg of body weight
Number of subjects: 6
Study 9046389 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g of ethanol/kg of body weight
Number of subjects: 6
Study 9046389 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 6
Study 9316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flumazenil
Number of subjects: 3
Study 9316697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 3238319 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (143 nmol i.v. bolus followed by 430 nmol infused at a constant rate over 90 min)
Number of subjects: 8
Study 3238319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 8
Study 31826827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI-based radiomic model
Number of subjects: 57
Study 31826827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI-based radiomic features
Number of subjects: 57
Study 29659952 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A diet adherence (tertile 3 compared with tertile 1)
Number of subjects: 973
Study 29659952 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B diet adherence (tertile 3 compared with tertile 1)
Number of subjects: 973
Study 29659952 — intervention group
Group type: EXPERIMENTAL
Intervention: Type AB diet adherence (tertile 3 compared with tertile 1)
Number of subjects: 973
Study 29659952 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A diet adherence after 6-month intervention
Number of subjects: 973
Study 29659952 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B diet adherence after 6-month intervention
Number of subjects: 973
Study 29659952 — intervention group
Group type: EXPERIMENTAL
Intervention: Type O diet adherence after 6-month intervention
Number of subjects: 973
Study 27140203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide
Number of subjects: 0
Study 27140203 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 25777546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2,000 IU
Number of subjects: 57
Study 25777546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4,000 IU
Number of subjects: 57
Study 25777546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25777546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (both doses)
Number of subjects: 57
Study 24105303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group (loading dose of 4°C cold saline, cooled to 32°C to 34°C for 48 hours)
Number of subjects: 98
Study 24105303 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 98
Study 24105303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group
Number of subjects: 98
Study 24105303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 24105303 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis on patients with pneumococcal meningitis
Number of subjects: 98
Study 24105303 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis
Number of subjects: 98
Study 21176107 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using reticulated open‐cell foam (ROCF)
Number of subjects: 21
Study 18347627 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Device (MD)
Number of subjects: 25
Study 18347627 — intervention group
Group type: COMPARATOR
Intervention: Finger Massage (FM)
Number of subjects: 25
Study 18347627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 17151173 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 12
Study 17151173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12697591 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane+nitrous oxide 60%
Number of subjects: 40
Study 12697591 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane+air in oxygen 40%
Number of subjects: 40
Study 12697591 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane+air in oxygen 40%
Number of subjects: 40
Study 12697591 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane+nitrous oxide 60%
Number of subjects: 40
Study 12697591 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (thiopental 5 mg kg(‐1), fentanyl 3 micro g kg(‐1), vecuronium 0.08 mg kg(‐1))
Number of subjects: 40
Study 10780136 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered computer-assisted health education (CAHE) program (Student Bodies)
Number of subjects: 60
Study 10780136 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 8814511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedalling at 50 r.min‐1
Number of subjects: 8
Study 8814511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedalling at 90 r.min‐1
Number of subjects: 8
Study 8814511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedalling at 110 r.min‐1
Number of subjects: 8
Study 8814511 — intervention group
Group type: COMPARATOR
Intervention: Comparison of W' at 50, 90, and 110 r.min‐1
Number of subjects: 8
Study 1383821 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP alone for 6 to 8 cycles
Number of subjects: 361
Study 1383821 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD for 12 cycles
Number of subjects: 361
Study 1383821 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD alone for 6 to 8 cycles
Number of subjects: 361
Study 1383821 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 361
Study 1383821 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 361
Study 6367375 — intervention group
Group type: COMPARATOR
Intervention: Preeclampsia
Number of subjects: 3
Study 6367375 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnancy
Number of subjects: 3
Study 6367375 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy
Number of subjects: 3
Study 6367375 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 3
Study 6367375 — intervention group
Group type: COMPARATOR
Intervention: 3 months after delivery
Number of subjects: 3
Study 31461390 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic frame
Number of subjects: 306
Study 31461390 — intervention group
Group type: COMPARATOR
Intervention: Episodic frame
Number of subjects: 306
Study 30405108 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet (n=38)
Number of subjects: 75
Study 30405108 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n=37)
Number of subjects: 75
Study 27912955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance groups conducted by experienced dance teachers for 45 minutes, three times a week for 16 weeks.
Number of subjects: 0
Study 27912955 — intervention group
Group type: COMPARATOR
Intervention: Music appreciation and socialisation groups for 45 minutes, three times a week for 16 weeks.
Number of subjects: 0
Study 27912955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance groups
Number of subjects: 0
Study 27912955 — intervention group
Group type: COMPARATOR
Intervention: Dance groups and music groups
Number of subjects: 0
Study 27912955 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Impairment Battery and Clinical Global Impression of Change
Number of subjects: 0
Study 24352377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40
Study 19152909 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (fluid restriction then nothing by mouth 12 hours before the procedure, water and simethicone at capsule ingestion)
Number of subjects: 150